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Background: Oxidized phosphatidylcholines (oxPC) and lysophosphatidylcholine (lysoPC) generated during the
formation of oxidized low-density lipoprotein (oxLDL) are involved in atherosclerotic lesion development. We
investigated the time course-changes in phosphatidylcholine (PC) molecular species during oxidation of LDL to
determine how those atherogenic PCs are produced.
Methods: Human and rabbit LDLs were pretreated with or without a selective platelet-activating factor
acetylhydrolase (PAF-AH) inhibitor. LDL was oxidized by incubation with copper sulfate, and PC profiles were
analyzed by liquid chromatography-tandem mass spectrometry.
Results: When human LDL was oxidized, the peak areas for polyunsaturated fatty acid (PUFA)-containing PC
species dramatically decreased after a short lag period, concomitantly lysoPC species increased sharply. Although a
variety of oxPC species containing oxidized fatty acyl groups or cleaved acyl chains are formed during LDL
oxidation, only a few oxPC products accumulated in oxLDL: 1-palmitoyl-2-(9-oxo-nonanoyl) PC and long-chain oxPC
with two double bonds. Pretreatment of LDL with the PAF-AH inhibitor greatly reduced lysoPC production while it
had no effect on lipid peroxidation reactions and oxPC profiles. Rabbit LDL, which has a different composition of
PC molecular species and needs a longer time to reach achieve full oxidation than human LDL, also accumulated
lysoPC during oxidation. The increase in lysoPC in rabbit oxLDL was suppressed by pretreatment with the PAF-AH
inhibitor. The major oxPC species formed in rabbit oxLDL were almost the same as human oxLDL.
Conclusions: These results suggest that lysoPC species are the major products and PAF-AH activity is crucial for
lysoPC generation during oxidation of LDL. The oxPC species accumulated are limited when LDL is oxidized with
copper ion in vitro.
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Oxidative modification of low-density lipoprotein (LDL)
is involved in atherosclerotic lesion development [1-3].
Studies have shown significant increases in plasma circu-
lating oxidized LDL (oxLDL) in patients with cardiovas-
cular diseases [4-8]. LDL consists of phospholipids,
cholesterol ester, triacylglycerol, and an apolipoprotein B
(apoB) together with several minor constituents, so that
oxLDL may contain a large variety of oxidized products
and modified molecules [9-11].
Many biological and pathological activities of oxLDL
have been investigated, and oxidized phosphatidylcholine
(oxPC) and lysophosphatidylcholine (lysoPC) formed
during oxidation of LDL are thought to be responsible
for some oxLDL functions. OxPC is a mixture of diverse
products characterized by various functional groups, in-
cluding both long chain acyl groups with hydroperoxide
or hydroxyl function and truncated short chain acyl
groups. Macrophage scavenger receptors take up oxLDL
leading to foam cell formation, where oxPC is involved
in recognition by scavenger receptors [12,13]. OxPC
could act as a peroxisome proliferator activating recep-
tor (PPAR)-γ activator to induce inflammatory and
metabolic responses [14]. It promotes chemokine pro-
duction in endothelial cells [15,16] and proliferation and
calcification of smooth muscle cells [17]. In addition,
oxPC induces inflammatory reactions by acting as an en-
vironmental pathogen mimetic [18]. OxPC, especially
PC hydroperoxides (PCOOH), increases macrophage ad-
hesion to ICAM-1 through reorganization of microfila-
ments [19]. LysoPC is another atherogenic metabolite
formed in oxLDL that shows many biological effects in-
cluding attenuation of endothelial functions and prolifer-
ation of smooth muscle cells [20,21].
OxPC is further modified chemically or enzymatically
in plasma. Several enzymes metabolize oxPC, including
phospholipid hydroperoxide glutathione peroxidase
(PHGPx) [22], secretory phospholipase A2 type IIA
(sPLA2-IIA) [23], lecithin-cholesterol acyltransferase
(LCAT) [24], and platelet-activating factor acetyl hydro-
lase (PAF-AH/Lp-PLA2) [25]. These enzyme activities
make oxidized PC profiles more complex.
PAF-AH is a unique plasma phospholipase that hydro-
lyzes PC species containing short and/or hydrophilic
acyl chains as substrates in addition to PAF itself [25,26].
It is considered that PAF-AH contributes substantially to
the detoxification of pro-atherogenic oxPC products into
lysoPC. Steinbrecher reported that the phospholipase A2
activity for short-chain PC substrates in human LDL was
not separated from PAF-AH [27]. The enzyme associates
with lipoprotein particles, LDL and high-density lipopro-
tein (HDL), in human plasma [25] and is found primarily
in association with HDL in rabbit and rodent plasma
[28,29]. Because PAF-AH has an active serine residue inits catalytic center, enzyme activity is inhibited by serine-
protease inhibitors such as phenylmethylsulfonyl fluoride
(PMSF). Pefabloc, a sufonylfluoride compound similar
to PMSF, does not inhibit paraoxonase-1, LCAT, or
venom phospholipase A2, has been used as a selective
inhibitor of PAF-AH [30-32].
Although the pathological impact of oxLDL is recog-
nized, neither the complete structure of oxLDL nor the
molecular process of oxLDL generation has been fully
determined. Recently liquid chromatography-tandem
mass spectrometry (LC-MS/MS) has been applied to the
comprehensive analysis PC molecular species including
oxidized products [33-35]. Rabbits have been used for
diet-induced atherosclerosis experiments, although many
animals including rodents are not susceptible to athero-
sclerosis without genetic manipulation. Checking PC
profiles of human and rabbit oxLDLs could give an idea
for atherogenic oxPC products. In the present study, we
investigated the PC profile changes during copper-
induced oxidation of LDL to elucidate the process of PC
modification by LC-MS/MS. We also investigated the
contribution of PAF-AH to PC profile changes using a
PAF-AH inhibitor and rabbit LDL in addition to human
LDL.
Results
PC profile change in human LDL during oxidation
Human LDL treated with or without pefabloc, a PAF-AH
inhibitor, was incubated with copper sulfate for up to 3 h
and the profile of PC molecular species was determined.
When human LDL was pretreated with pefabloc for
30 min, 98% of the PAF-AH activity was inhibited, as deter-
mined using 2-thio-PAF as substrate. Pretreatment of LDL
with pefabloc showed no differences in increases of thiobar-
bituric acid-reactive substances (TBARS) and electromobi-
lity shift in agarose gel electrophoresis during oxidation
(Figure 1), suggesting that peroxidation reactions in the
LDL proceed equally in pefabloc-treated LDL and non-
treated LDL.
Using LC-MS/MS with multiple-reaction monitoring
(MRM), 42 PC species with selected m/z values were de-
tected simultaneously in each oxLDL sample (Table 1).
These PC species were classified into five groups: PC
containing polyunsaturated fatty acids (PUFA-PC), PC
with only saturated or monounsaturated fatty acids
(S/MUFA-PC), lysoPC, oxPC with truncated acyl chains
(cleaved oxPC), and oxPC with oxidized acyl chains
(long chain oxPC). Figure 2 shows the changes in peak
area of each PC species during copper-induced oxidation
of human LDL. PUFA-PC species did not change for the
first 30 min, then decreased dramatically (Figure 2A),
whereas S/MUFA-PC did not change throughout the in-
cubation (Figure 2B). LysoPC species, primarily 16:0-
LPC and 18:0-LPC, increased gradually until 30 min and
Figure 1 Time course of copper-induced oxidation of human
LDL. Human LDL (0.2 mg/mL) treated either with or without a PAF-AH
inhibitor, pefabloc, was incubated with copper sulfate (5 μM) at 37°C
for up to 3 h. The oxidative change of LDL during the incubation was
evaluated by production of TBARS (A) and relative mobility on agarose
gel electrophoresis (B). Values indicated are mean ± SD of 8–10
experiments.
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(Figure 2C). The amounts of oxPC increased slightly
throughout the incubation period. Many oxPC species
were formed, but the major product appeared to be 1-
palmitoyl-2-(9-oxo-nonanoyl) PC (PONPC; m/z = 650.6)
(Figure 2D). Among the long-chain oxPC, species with
two double bonds, derived from linoleate-containing PCs,
accumulated during the incubation period. In contrast,
those with four double bonds, likely derived from
arachidonate-containing PCs, did not accumulate or even
decreased after 1 h incubation (Figure 2E).
Figure 3 shows the PC profile changes during the oxida-
tion of pefabloc treated-human LDL. After the lag time,
PUFA-PC species began to decrease at 60 min and S/
MUFA-PC did not change throughout the incubation
(Figure 3A, B). LysoPC species increased during the incuba-
tion, although the peak areas were much smaller than those
without pefabloc treatment (Figure 3C). The major oxPCspecies accumulated were PONPC and long-chain oxPC
species with two double bonds (Figure 3D, E) that were also
the major species in the absence of pefabloc treatment.
We calculated the increase or decrease of peak area ob-
tained after the 3 h incubation period for each species to
see the effect of pefabloc on the PC profiles (Figure 4). All
of the PUFA-PC reduced their peak areas, showing that in-
hibition of PAF-AH had little effect on changes in PUFA-
PC following treatment with copper sulfate (Figure 4A).
LysoPC increased their peak areas during the oxidation re-
action, and the increase of lysoPC was greatly suppressed
when PAF-AH was inhibited (Figure 4C). Pefabloc treat-
ment had limited effect on the increase of cleaved oxPC
and long-chain oxPC species, while cleaved oxPC species
with five carbon-acyl chains (m/z = 594.2, 610.6 and 622.6)
increased slightly (Figure 4D, E).
PC profiles in rabbit LDL during oxidation
Next, we examined changes in the PC profile in
rabbit LDL during oxidation. LDL was prepared from
New Zealand white rabbits fed normal diet supple-
mented with 0.5% cholesterol to increase LDL content
in plasma. The PC profile of rabbit LDL is substan-
tially different from that of human LDL. Rabbit LDL
is relatively rich S/MUFA-PC and lysoPC. Rabbit LDL
was needed a longer incubation than human LDL to
reach the maximum oxidation, which may be caused
by lower content of PC species with more than five
double bonds. PAF-AH activity in the rabbit LDL
fraction was estimated to be 2.9 nmol/min/mg, which
is 25% of that in human LDL. The PAF-AH activity
in the LDL fraction was 6.0% of HDL fraction recov-
ered from the same rabbits, which corresponds to a
previous report that PAF-AH is present mostly in
HDL in rabbit plasma and very little in LDL [28].
Pretreatment of the rabbit LDL fraction with pefabloc
reduced PAF-AH activity by 91%.
Rabbit LDL, with or without pefabloc treatment,
was incubated with copper sulfate for up to 8 h, and
the profiles of PC molecular species were determined.
Figures 5 and 6 show the time-course changes in
peak area of each PC molecular species in rabbit
oxLDL. The profile of S/MUFA-PC did not change
throughout the incubation, and PUFA-PC appeared to
decrease after 1 h (Figures 5A, 5B, 6A, and 6B).
LysoPC increased during oxidation of rabbit LDL but
it did not when rabbit LDL was pretreated with PAF-AH
inhibitor (Figures 5C, 6C). These results, together
with those from human oxLDL, indicate that the con-
tribution of PAF-AH is required for lysoPC formation
during oxidative modification of LDL. Many of the
oxPC species increased their peak areas during the
oxidation, however the major species accumulated in
rabbit oxLDL, PONPC and long-chain oxPC with two
able 1 List of 42 PC species monitored by LC-MS/MS
/z Molecular species m/z Molecular species
/MUFA-PC Long chain oxPC
32.6 32:1 772.6 34:2 + 14
34.6 32:0 774.6 34:2 + 16
60.6 34:1* 790.6 34:2 + 32
88.6 36:1 796.6 36:4 + 14
90.6 36:0 798.6 36:4 + 16
78.4 28:0* 814.6 36:4 + 32
800.6 36:2 + 14
UFA-PC 802.6 36:2 + 16
56.6 34:3 818.6 36:2 + 32
58.6 34:2* 824.6 38:4 + 14
80.6 36:5 826.6 38:4 + 16
82.6 36:4* 842.6 38:4 + 32
84.6 36:3
86.6 36:2 Cleaved oxPC
06.6 38:6 594.6 1-palmitoyl-2-(5-oxovaleroyl) PC*
08.6 38:5 610.6 1-palmitoyl-2-glutaroyl PC*
10.6 38:4 622.6 1-stearoyl-2-(5-oxovaleroyl) PC
34.6 40:6 638.6 1-stearoyl-2-glutaroyl PC
650.6 1-palmitoyl-2-(9oxo-nonanoyl)PC*
ysoPC 664.6 1-palmitoyl-2-(5-oxo-octenoyl) PC
96.2 16:0-lysoPC* 666.6 1-palmitoyl-2-azelaoyl PC*
24.2 18:0-lysoPC 692.6 1-stearoyl-2-(5-oxo-octenoyl) PC
94.2 16:1-lysoPC 706.6 1-stearoyl-2-(6-oxo-nonenoyl) PC
22.2 18:1-lysoPC 652.6a 1-O-hexadecyl-2-azelaoyl PC*
MRM mode, signals corresponding to selected m/z values with a fragment ion of 184 were selectively detected. *PC species identified by comparison with
ommercially available synthetic standard PC species. The other species are inferred from MS data available in the literature.



























cdouble bonds, were the same as those in human
oxLDL (Figures 5D, 5E, 6D and 6E).
Figure 7 shows the change of peak area for each spe-
cies after the 8 h incubation of rabbit LDL with or with-
out pefabloc treatment. It was observed again that
pretreatment of LDL with pefabloc had no effect on the
behavior of PUFA-PC and S/MUFA-PC during the oxi-
dation of rabbit LDL, which is very similar to human
LDL (Figure 7A, B). LysoPC increased their peak areas
during the oxidation reaction, and the lysoPC formation
was suppressed in pefabloc-treated LDL (Figure 7C).
Pefabloc treatment had enhanced the accumulation of
cleaved oxPC species and suppressed long-chain oxPC
species with two double bonds (Figure 7D, E).
Protein modification with oxPC
During oxidation of LDL, apoB-oxPC adducts are formed
and can be detected by sandwich ELISA using antibodies
recognizing oxPC and apoB [36]. Inhibition of PAF-AH ac-
tivity in human LDL increased apoB-oxPC adducts formedin oxLDL, as judged from immunoreactivity in sandwich
ELISA (Figure 8). PAF-AH hydrolyzes oxPC species with
short and hydrophilic acyl chains including chemically re-
active aldehyde derivatives [26]. We accordingly speculate
that PAF-AH is protective to apoB-oxPC adduct formation.Discussion
OxLDL is thought to be an important factor in atheroscler-
osis. Evidence is accumulating that the plasma level of
in vivo oxLDL is a predictor of cardiovascular disease [4-8].
Previous studies revealed that many atherogenic oxPCs and
lysoPC are formed in oxLDL [12,15,18,20]. However, the
manner in which LDL is oxidatively modified remains to be
determined. In this study we analyzed the time-course
changes in the PC profile during LDL oxidation using LC-
MS/MS to view the full picture of oxPC generation and the
contribution of PAF-AH. Our study shows that PAF-AH
has a crucial role in generating lysoPC during LDL oxida-
tion. Many cleaved oxPC and long-chain oxPC species are
Figure 2 PC profile changes during copper-induced oxidation of human LDL. Human LDL (0.2 mg/mL) was incubated with copper sulfate
(5 μM) at 37°C for up to 3 h. Lipids were extracted by the Bligh and Dyer method from 10 μg of oxLDL after addition of 20 pmol of didecanoyl
PC as internal standard. Total lipid extract was subjected to LC-MS/MS analysis to detect 42 PC and modified PC molecular species by MRM mode,
and they were classified into five categories: PUFA-PC (A), S/MUFA-PC (B), lysoPC (C), cleaved-chain oxPC (D) and long-chain oxPC (E). The peak
area (cps) for each species was normalized based on the peak areas of internal standard, and the means and SD were calculated from six
independent preparations. Statistical significance of comparison with the sample without incubation (0 min) was calculated by ANOVA; *, p < 0.05;
#, p < 0.01; +, p < 0.005; **, p < 0.001.
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accumulating in oxLDL.
By simultaneously and selectively detecting 42 PC species
in a sample using MRM mode of LC-MS/MS, we followed
changes in PC profiles during copper-induced oxidation.Because standards for all of the PC species were not avail-
able, absolute quantitation of the PC profiles cannot be
completed. The data are shown as the relative peak areas of
the PC species after normalizing on the basis of internal
standard. As expected, most of the PUFA-PC species
Figure 3 PC profile changes during copper-induced oxidation of human LDL treated with a PAF-AH inhibitor. Human LDL was
pretreated with pefabloc, a PAF-AH inhibitor, and the treated LDL (0.2 mg/mL) was incubated with copper sulfate (5 μM) at 37°C for up to 3 h.
Lipid extraction and LC-MS/MS analysis were performed as in Figure 2. The peak area (cps) for each species was normalized based on the peak
areas of internal standard, and means and SD were calculated from six independent preparations. The 42 PC species were classified into five
groups: PUFA-PC (A), S/MUFA-PC (B), lysoPC (C), cleaved-chain oxPC (D) and long-chain oxPC (E). Statistical significance of comparison with the
sample without incubation (0 min) was calculated by ANOVA; *, p < 0.05; #, p < 0.01; +, p < 0.005; **, p < 0.001.
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whereas S/MUFA-PC did not change. Long-chain oxPC
with four double bonds were unstable and appeared transi-
ent. Interestingly, only a few oxPC species accumulated in
fully oxidized LDL in vitro, namely PONPC (m/z = 650.6)
and mono-oxygenated forms of linoleate-containing PC. It
is likely that oxPC species derived from PC containing
more than four double bonds are so susceptible to furthermodification either by chemically or enzymatically that they
cannot accumulate in oxLDL.
PCOOH, detected as long chain oxPC species with
m/z +32, was present in LDL but was not the major
products in oxLDL (Figures 2, 3, 4, 5, 6 and 7, and
Additional file 1 for enlarged graphs). Kinoshita, et al.
determined the PCOOH concentration in human plasma
from healthy control was 160 nmol/L using HPLC with
Figure 4 Effects of PAF-AH inhibitor pretreatment on changes in PC species during oxidation of human LDL. Human LDL and
pefabloc-treated human LDL (0.2 mg/mL) were incubated with copper sulfate (5 μM) at 37°C for 3 h. Lipid extraction and LC-MS/MS analysis were
performed, and the change in peak area (cps) during the 3 h oxidation was calculated for each PC species. The 42 PC species were classified into
five groups: PUFA-PC (A), S/MUFA-PC (B), lysoPC (C), cleaved-chain oxPC (D) and long-chain oxPC (E). Values indicated are means and SD (n = 6).
Statistical significance between the samples with and without treatment with PAF-AH inhibitor was calculated by Welch t-test; *, p < 0.05;
#, p < 0.01; +, p < 0.005; **, p < 0.001.
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tion increased to approximately 2-fold in plasma from
patients with hyperlipidemia, however, the ratio of
PCOOH in total PC was still 1/7,000. Our data cannot
directly transfer to quantitative calculations, but rela-
tively small peaks for PCOOH in the human and rabbit
LDLs among all the PC species (Figures 2 and 5) corre-
sponds well to the previous study.
LysoPC appeared to be the major product in oxLDL.
Its generation was strongly suppressed by pefabloc treat-
ment of both human and rabbit LDL, suggesting that
PAF-AH activity is critical for lysoPC generation in LDL.
It is well known that PAF-AH can act on PC species
with hydrophilic short chain acyl groups, in addition to
PAF, to produce lysoPC [26]. Thus it is speculated that
pefabloc treatment of LDL increases some oxPC species
that are substrates of PAF-AH during oxLDL formation.
The peak areas for several cleaved oxPC species further
increased by the pefabloc treatment (Figures 4D
and 7D). However, the major oxPC species thataccumulated in pefabloc-treated LDL during oxidation
was almost the same as that of oxLDL with active PAF-
AH. Our observation agrees with a previous report by
Davis et al., in which an oxPC profile in LDL oxidized
with copper sulfate for 20 h was analyzed [35].
In addition to hydrolysis of cleaved oxPC species, the
protective role of PAF-AH in oxLDL modification was
suggested by oxPC-apoB adduct formation. Some chem-
ically active oxPC may react with proteins to form ad-
ducts, and extensive hydrolysis of oxPC by PAF-AH is
protective against apoB modification by oxPC products.
LysoPC generation was largely inhibited in pefabloc-
treated oxLDL, but still a very small increase in lysoPC
remained. A possible explanation for this observation is
non-enzymatic hydrolysis of oxPC. Choi, et al. reported
that lysoPC can be generated through spontaneous
deacylation of cleaved-chain oxPC products such as
1-palmityl-2-(4-hydroxy-7-oxo-5-heptenoyl)-PC [38]. Alter-
natively, other oxPC-hydrolyzing enzymes may distribute in
part to LDL and contribute to lysoPC formation. We
Figure 5 PC profile changes during copper-induced oxidation of rabbit LDL. Rabbit LDL (0.1 mg/mL) was incubated with copper sulfate
(5 μM) at 37°C for up to 8 h. Lipid extraction and LC-MS/MS analysis were performed as in Figure 2. The peak area (cps) for each species was
normalized based on the peak areas of internal standard, and the means and SD were calculated from six independent preparations. The 42 PC
and modified PC molecular species by MRM mode, and they were classified into five categories: PUFA-PC (A), S/MUFA-PC (B), lysoPC (C),
cleaved-chain oxPC (D) and long-chain oxPC (E). Statistical significance of comparison with the sample without incubation (0 h) was calculated
by ANOVA; *, p < 0.05; #, p < 0.01; +, p < 0.005; **, p < 0.001.
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only hydrolyzed by PAF-AH but also further modified or
decomposed in PAF-AH-independent manners.
Inhibition of PAF-AH in apoE-knockout mice resulted
in reduction in atherosclerotic lesion size [39]. However,
another study reported that adenoviral overexpression ofPAF-AH prevents injury-induced neointima in apoE-
knockout mice [40]. A PAF-AH inhibitor has been inves-
tigated in clinical trials and the prevention of expansion
of necrotic core lesions in human was shown, however,
the roles of PAF-AH in atherogenesis and oxLDL modi-
fication remain uncertain [41]. Our study suggests that
Figure 6 PC profile changes during copper-induced oxidation of rabbit LDL treated with PAF-AH inhibitor. Rabbit LDL (0.1 mg/mL) was
treated with a PAF-AH inhibitor, pefabloc, and then, incubated with copper sulfate (5 μM) at 37°C for up to 8 h. Lipid extraction and LC-MS/MS
analysis were performed as in Figure 2. The peak area (cps) for each species was normalized based on the peak areas of internal standard, and
the means and SD were calculated from six independent preparations. The 42 PC species were classified into five groups: PUFA-PC (A), S/MUFA-PC
(B), lysoPC (C), cleaved-chain oxPC (D) and long-chain oxPC (E). Statistical significance of comparison with the sample without incubation (0 h) was
calculated by ANOVA; *, p < 0.05; #, p < 0.01; +, p < 0.005; **, p < 0.001.
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little effect on oxPC accumulation. To understand the
effects of PAF-AH on atherosclerosis, the pathological
roles of atherogenic oxPC and lysoPC should be
elucidated.
It should be noted that the current study focused on
oxLDL prepared in vitro. This study is an important step
toward understanding the complex nature of oxidizedlipoproteins. Elucidation of the contribution of oxLDL
to atherogenesis awaits further lipidomic and proteomic
studies to characterize the features of circulating oxLDL.
Conclusions
We determined the PC profile of oxLDL using a lipido-
mic approach. The major products in copper-induced
oxLDL were lysoPC species, and PAF-AH plays a critical
Figure 7 Effects of PAF-AH inhibitor pretreatment on changes in PC species during oxidation of rabbit LDL. Rabbit LDL and
pefabloc-treated rabbit LDL (0.1 mg/mL) were incubated with copper sulfate (5 μM) at 37°C for 8 h. Lipid extraction and LC-MS/MS analysis were
performed, and the change in peak area (cps) during the 8 h oxidation was calculated for each PC species. The 42 PC species were classified into
five groups: PUFA-PC (A), S/MUFA-PC (B), lysoPC (C), cleaved-chain oxPC (D) and long-chain oxPC (E). Values indicated are means and SD (n = 6).
Statistical significance between the samples with and without treatment with PAF-AH inhibitor was calculated by Welch t-test; *, p < 0.05;
#, p < 0.01; +, p < 0.005; **, p < 0.001.
Sasabe et al. Lipids in Health and Disease 2014, 13:48 Page 10 of 13
http://www.lipidworld.com/content/13/1/48role in lysoPC generation in LDL. Although many oxPC
species are generated, PONPC and long-chain oxPC spe-
cies derived from linoleate-containing PC are the major
products accumulating in oxLDL. These observations
shed light on the manner in which oxPCs are modified
and metabolized.Methods
Preparation and oxidation of human LDL
Human LDL and oxLDL were prepared as described
previously [9]. This study was approved by the Ethical
Committee of Showa University. In brief, plasma was
separated from human blood from healthy volunteers by
centrifugation at 2,000 rpm for 10 min, after which
EDTA was added to the plasma (final concentration
0.25 mM). LDL was separated from the human plasma
using sequential ultracentrifugation, with addition of
KBr to adjust the density, and then dialyzed against PBS
containing 0.25 mM EDTA to remove the KBr. Theprotein concentration of the LDL fraction was deter-
mined by the BCA method using BSA as standard.
To inhibit PAF-AH activity of LDL, an aliquot of the LDL
fraction (1 mg/mL) was incubated with pefabloc (Boehringer,
0.5 mM) at 37°C for 30 min [30]. The LDL was then passed
through a PD-10 desalting column (BioRad) to remove
excess pefabloc. The PAF-AH activity was estimated using a
PAF-AH assay kit (Cayman Chemicals).
Either LDL or pefabloc-treated LDL (0.2 mg/mL) was
incubated with CuSO4 (5 μM) at 37°C for up to 3 h. At
the end of the incubation period, 1 μL of 250 mM EDTA
was added to stop copper-induced oxidation. Oxidation
reaction was evaluated by measurement of TBARS and
agarose-gel electromobility assay. After mixtures of
100 μL of sample and 200 μL of TBA reagent (0.375%
TBA, 15% trichloroacetic acid, and 0.25 M HCl) were
boiled for 15 min, absorbance was measured at 535 nm
[42]. Electromobility of oxLDL was evaluated on a 0.5%
agarose gel using barbiturate buffer at pH 8.6. Determin-
ation of immunoreactivity to an anti-oxPC monoclonal
Figure 8 Immunoreativity of human oxLDL to antibodies
against oxPC and apoB. Human LDL (0.2 mg/mL) treated either
with or without a PAF-AH inhibitor, pefabloc, was incubated with
copper sulfate (5 μM) at 37°C for up to 3 h. Oxidative changes of
immunoreactivity by sandwich ELISA using antibodies against oxPC
and apoB were evaluated. Relative immunoreactivity was calculated
from 10 experiments. Statistical significance between samples with
and without pefabloc treatment was calculated by Welch t-test;
*, p < 0.05.
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formed by sandwich ELISA as described previously [36].
Preparation and oxidation of rabbit LDL
New Zealand White rabbits (6–7 weeks old) were pur-
chased from Kitayama Labes Co., Ltd. (Nagano, Japan).
The study protocol was approved by the Animal Care
Committee (permit no. 11–0221) and carried out in ac-
cordance with the “Guideline for Animal Care and
Use at the Otsuka Pharmaceutical Co. Ltd.”. The rabbits
were acclimated and fed a cholesterol-enriched diet con-
taining 0.5% cholesterol (w/w) in a standard rabbit chow
(RC4; Oriental Yeast Co. Ltd.) at 80 g/day for 10 weeks
as previously described [43]. Blood was collected from
the inferior vena cava in EDTA-treated syringes under
pentobarbital anesthesia. Then LDL fraction was col-
lected from plasma by centrifugation, 0.25 mM EDTA
was added, and LDL was stored in tubes filled with
argon gas in a refrigerator. After LDL was dialyzed
against PBS in a refrigerator, 5 μM CuSO4 was added to
100 μg/mL of LDL and incubated for up to 8 h at 37°C.
The oxidation reaction was stopped by addition of
EDTA (final 0.25 μM) to the solution. The oxLDL was
stored in tubes filled with argon gas at −80°C.
LC-MS/MS analysis of oxPC
The profile of PC molecular species in LDL and oxLDL
was determined by LC-MS/MS (AB SCIEX, QTRAP5500
equipped with Shimadzu LC-10A). LC separations wereperformed on an Inertsil SIL-100A column (2.1 × 150mm,
GL Science, Tokyo, Japan) with elution solvent of aceto-
nitrile/methanol/3% formic acid (18/11/8 (v/v/v)) at a flow
rate 200 μL/min as described by Morishita et al. [44]. The
synthetic PC standards, didecanoyl-PC, 1-pentadecanoyl-2-
lysoPC, PONPC were purchased from Avanti Polar Lipid
Inc. Total lipids were extracted from 10 μg of oxLDL by
the Bligh and Dyer method [45]. To the recovered chloro-
form phase, didecanoyl-PC (20 pmol) was added as internal
standard. The samples were dried under N2 gas and the
dissolved in 200 μL of the elution solvent. For each analysis,
10 μL of the sample was injected. PC species were detected
and quantified using MRM procedure, in which 42 selected
ions releasing a fragment ion of m/z = 184 corresponding
to a phosphorylcholine group were detected.
Statistics
Data are presented as means ± standard deviation (SD). For
the statistical analysis, one-way-ANOVA was carried out,
and a p value < 0.05 was taken to be significant.
Additional file
Additional file 1: Enlarged figures for PC profile changes during
copper-induced oxidation of human and rabbit LDL. Some bar
graphs of the PC species shown in the Figures 2, 3, 5 and 6 were too
small to see (less than 1 × 107 cps), this file shows the detail of the PC
profile changes of the minor species. The time course changes of PC
species during oxidation of human LDL with or without pefabloc
pretreatment (A, B) are shown in an enlarged scale. The time course
changes of ten PC species during oxidation of rabbit LDL with or without
pefabloc (C, D) are shown in an enlarged scale. Statistical significance of
comparison with the sample without incubation (0 min) was calculated
by ANOVA; *, p < 0.05; #, p < 0.01; +, p < 0.005; **, p < 0.001.
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